Register for our free email digests:
Aidan Fry

Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Aidan Fry
Egypt’s Rameda Prices Public Offering
Through an initial public offering, Egyptian branded generics supplier Rameda intends to raise funds to buy both products and companies in the Middle East and North Africa.
Ophthalmics Are Next Frontier For Teligent
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.
IPA Honors DG Shah With Public-Policy Award
In honor of its former secretary-general DG Shah, the Indian Pharmaceutical Alliance has created a public policy award at the Indian Institute of Management in Ahmedabad.
Advanz Sees Mumbai Center As Strategic Strength
Using its Indian back-office function to realize synergies from acquired sales and marketing assets in western Europe forms a key part of Advanz Pharma’s growth strategy.
Emcure Aims To Split Itself In Half
By the middle of next year, Emcure intends to have demerged its operations in highly developed markets from its activities in India and other emerging markets. The Indian group is seeking private-equity support to grow inorganically in North America and Europe.
Hikma Sets Injectables Sights On France, Spain and Canada
With added steriles capacity coming online, Hikma is looking soon to expand its Injectables business unit into France and Spain. The company is also considering options for marketing injectable drugs in Canada.